Editorial: golimumab thresholds to achieve stringent medium‐ and long‐term therapeutic outcomes in patients with ulcerative colitis

Abstract

LINKED CONTENTThis article is linked to Taxonera et al papers. To view these articles, visit https://doi.org/10.1111/apt.16964 and https://doi.org/10.1111/apt.17118

Editorial: golimumab thresholds to achieve stringent medium‐ and long‐term therapeutic outcomes in patients with ulcerative colitis—Author’s reply

“…I thank Mantzaris and Papamichael for their comments and interest in our study evaluating the exposure–response relationship of serum golimumab trough concentrations (GTC) during maintenance therapy with outcomes, including endoscopic healing and histologic remission, in patients with ulcerative colitis (UC) 1,2 …”